208 related articles for article (PubMed ID: 36706355)
1. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Penter L; Liu Y; Wolff JO; Yang L; Taing L; Jhaveri A; Southard J; Patel M; Cullen NM; Pfaff KL; Cieri N; Oliveira G; Kim-Schulze S; Ranasinghe S; Leonard R; Robertson T; Morgan EA; Chen HX; Song MH; Thurin M; Li S; Rodig SJ; Cibulskis C; Gabriel S; Bachireddy P; Ritz J; Streicher H; Neuberg DS; Hodi FS; Davids MS; Gnjatic S; Livak KJ; Altreuter J; Michor F; Soiffer RJ; Garcia JS; Wu CJ
Blood; 2023 Apr; 141(15):1817-1830. PubMed ID: 36706355
[TBL] [Abstract][Full Text] [Related]
2. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
3. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
[TBL] [Abstract][Full Text] [Related]
4. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
5. Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
Ren Y; Liu F; Chen X; Zhang X; Zhao B; Wan Y; Lan Y; Li X; Yang W; Zhu X; Guo Y
Ann Hematol; 2024 Apr; 103(4):1345-1351. PubMed ID: 38316642
[TBL] [Abstract][Full Text] [Related]
6. [Effect and safety of 10-day decitabine-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation in 31 patients with acute myeloid leukemia/myelodysplastic syndrome].
Liu J; Cao YG; Zhang RL; Zhai WH; Chen X; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):472-478. PubMed ID: 37550202
[No Abstract] [Full Text] [Related]
7. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Penter L; Zhang Y; Savell A; Huang T; Cieri N; Thrash EM; Kim-Schulze S; Jhaveri A; Fu J; Ranasinghe S; Li S; Zhang W; Hathaway ES; Nazzaro M; Kim HT; Chen H; Thurin M; Rodig SJ; Severgnini M; Cibulskis C; Gabriel S; Livak KJ; Cutler C; Antin JH; Nikiforow S; Koreth J; Ho VT; Armand P; Ritz J; Streicher H; Neuberg D; Hodi FS; Gnjatic S; Soiffer RJ; Liu XS; Davids MS; Bachireddy P; Wu CJ
Blood; 2021 Jun; 137(23):3212-3217. PubMed ID: 33720354
[TBL] [Abstract][Full Text] [Related]
8. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
Xuan L; Dai M; Jiang E; Wang Y; Huang F; Fan Z; Xu N; Nie D; Liang X; Chen H; Ye J; Shi P; Liu H; Jin H; Lin R; Yan C; Zhang Y; Sun J; Han M; Liu Q
Lancet Haematol; 2023 Mar; 10(3):e178-e190. PubMed ID: 36702138
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen.
Lai B; Mu Q; Zhang Y; Chen Y; Yan X; Ouyang G
Hematology; 2021 Dec; 26(1):751-757. PubMed ID: 34555298
[TBL] [Abstract][Full Text] [Related]
10. Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms.
Tamura M; Yonezawa T; Liu X; Asada S; Hayashi Y; Fukuyama T; Tanaka Y; Kitamura T; Goyama S
Sci Rep; 2019 Jun; 9(1):8171. PubMed ID: 31160638
[TBL] [Abstract][Full Text] [Related]
11. Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study.
Xu W; Ye L; Mei C; Zhou XP; Ren Y; Ma L; Ye X; Lu C; Jin J; Tong HY
Leuk Lymphoma; 2021 Aug; 62(8):1920-1929. PubMed ID: 33682621
[TBL] [Abstract][Full Text] [Related]
12. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].
Zhou J; Wang J; Liu H; Zheng H; Ma L; Wang P; Yan S; Wu D; Fu C; Qiu H; Tang X; Jin Z; Han Y; Miao M
Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(12):920-4. PubMed ID: 26081055
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
17. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of Decitabine Therapeutic Effeicacy for Patients with Relapsed MDS/AML and High-Risk AML Patients after HSCT].
Wang QY; Liang ZY; Dong YJ; Yin Y; Wang Q; Liu W; Xu WL; Li Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):248-254. PubMed ID: 32027285
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
Davids MS; Kim HT; Bachireddy P; Costello C; Liguori R; Savell A; Lukez AP; Avigan D; Chen YB; McSweeney P; LeBoeuf NR; Rooney MS; Bowden M; Zhou CW; Granter SR; Hornick JL; Rodig SJ; Hirakawa M; Severgnini M; Hodi FS; Wu CJ; Ho VT; Cutler C; Koreth J; Alyea EP; Antin JH; Armand P; Streicher H; Ball ED; Ritz J; Bashey A; Soiffer RJ;
N Engl J Med; 2016 Jul; 375(2):143-53. PubMed ID: 27410923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
